Self-regulating networks dictate the genetic program of tumor cells

September 25, 2012

Scientists at Charité – Universitätsmedizin Berlin could explain a yet unknown regulatory network that controls the growth of tumor cells. Understanding such networks is an important task in molecular tumor biology in order to decode the relationships between the determinants defining which molecules are produced and in what quantities, in both normal and tumor cells. The study is published in the journal Molecular Systems Biology.

The growth of a tumor and its reaction to specifically targeted therapy is dictated by changes in its genetic material (mutations) encoding special signal molecules. These molecules activate the genetic program of tumor cells via branched signalingpathways and influence all processes needed for cell division, the mobility of cells and metastasis. Significant steering elements of these tumor-specific programs are called transcription factors. These are molecules that selectively control the transcription of the cell's genetic information (DNA) into and enable production of proteins . Altogether a complex network of mutually regulating transcription factors is activated.

Whereas the signal network in human tumors has already been characterized very well, it is hardly understood how transcription factors cooperate and regulate each other. In order to explain this transcription factor network, the scientists used a approach. A complex experimental data set—in which the in were systematically disrupted—was analyzed with the help of mathematical modeling. As a result, interactions within the network could be reconstructed and the network controlling tumor growth clarified.

"Contrary to a current assumption, the results show that no superordinate transcription factor exists that controls the activity of other factors as a master regulator," explains Prof. Reinhold Schäfer, head of the Laboratory for Molecular Tumor Pathology and deputy director of the Charité Comprehensive Cancer Center. Instead, two hierarchical groups of interacting factors exist. Each of them activates gene sets needed for growth and cancer-specific properties of the cells. The results indicate that new therapeutic approaches against tumors must target multiple rather than singular factors and consider the network structures.

Explore further: What causes brain cancer? Understanding glioblastoma at the genetic, molecular level

More information: Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Blüthgen N, Schäfer R. Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS. Mol Syst Biol. 2012 Jul 31;8:601. doi: 10.1038/msb.2012.32

Related Stories

What causes brain cancer? Understanding glioblastoma at the genetic, molecular level

July 6, 2011
Glioblastoma is the most common and most lethal form of brain tumor in people. Research published in the International Journal of Computational Biology and Drug Design offers a novel way to determine what biological functions ...

Researchers and colleagues identify PHF20, a regulator of gene P53

August 24, 2012
Researchers at Moffitt Cancer Center and colleagues have identified PHF20, a novel transcriptional factor, and clarified its role in maintaining the stability and transcription of p53, a gene that allows for both normal cell ...

Disappearance of genetic material allows tumor cells to grow

August 4, 2011
Malignant Sézary syndrome is characterized by the reproduction of a special type of white blood cells in the skin of male and female patients. In contrast to most other skin lymphomas, patients with Sézary syndrome ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.